Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study [Gastrointestinal Cancer]

Conclusion
In patients with G13D-mutated chemotherapy-refractory mCRC, there was no statistically significant improvement in disease control at 6 months with either cetuximab monotherapy or cetuximab plus irinotecan. No responses were seen with single-agent cetuximab. The responses observed with the combination of cetuximab and irinotecan may reflect true drug synergy or persistent irinotecan sensitivity. The ICECREAM (Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Among Patients with a G13D Mutation) study demonstrates the need to prospectively evaluate hypotheses that were previously supported by retrospective analyses and exemplifies the value of international collaboration in trials of rare molecular subtypes.

Source: Journal of Clinical Oncology - June 21, 2016 Category: Cancer & Oncology Authors: Segelov, Thavaneswaran, Waring, Desai, Robledo, Gebski, Elez, Nott, Karapetis, Lunke, Chantrill, Pavlakis, Khasraw, Underhill, Ciardiello, Jefford, Wasan, Haydon, Price, van Hazel, Wilson, Simes, Shapiro Tags: Translational Oncology, Gastrointestinal Gastrointestinal Cancer Source Type: research